-
公开(公告)号：US20120265283A1
公开(公告)日：2012-10-18
申请号：US13086664
申请日：2011-04-14
Applicant: MATTHEW M. MACK , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
Inventor： MATTHEW M. MACK , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
IPC: A61M25/10 , A61M25/098 , A61F2/84
CPC classification number: A61M25/1011 , A61F2/958 , A61M25/10182 , A61M25/10185 , A61M25/10188 , A61M25/104 , A61M2025/0004 , A61M2025/0006 , A61M2025/1013 , A61M2025/1015 , A61M2025/1052 , A61M2025/1079
Abstract: A catheter configured for performing reperfusion by alternatively occluding a vessel so as to prevent fluid flow and removing that occlusion to allow fluid flow is described. A first catheter includes an outer member and a retractable valve to allow and prevent fluid flow in the vessel. A second catheter includes a sheathed expansion member that can be deployed and recaptured to prevent and allow, respectively, fluid flow. A third catheter includes an angioplasty balloon to open a vessel occlusion, in which an occlusion balloon is used to allow and disallow fluid flow. A fourth catheter includes an expandable member for providing mechanical plunging action to urge thrombotic material to a more distal location. A fifth catheter includes an accessory catheter that can be used to perform reperfusion with another catheter. A sixth catheter includes an inner balloon within an outer balloon configured to perform reperfusion.
Abstract translation: 导管，被配置为通过交替地封闭容器进行再灌注，以便防止流体流动并且去除该阻塞以允许流体流动。 第一导管包括外部构件和可伸缩阀，以允许和防止流体在容器中流动。 第二导管包括可以展开和重新捕获以防止和允许流体流动的护套膨胀构件。 第三导管包括血管成形术球囊以打开血管闭塞，其中使用阻塞气囊来允许和禁止流体流动。 第四导管包括用于提供机械插入作用以将血栓形成材料推动到更远侧位置的可扩张构件。 第五导管包括可用于对另一个导管进行再灌注的辅助导管。 第六导管包括构造成执行再灌注的外气囊内的内气球。
-
2.发明授权公开(公告)号：US08038991B1
公开(公告)日：2011-10-18
申请号：US11933922
申请日：2007-11-01
Applicant: John J. Stankus , Eugene Michal , Mikael Trollsas , Brandon Katz , Shubhayu Basu
Inventor： John J. Stankus , Eugene Michal , Mikael Trollsas , Brandon Katz , Shubhayu Basu
IPC: C12N5/00
CPC classification number: A61K31/00 , A61K9/0024 , A61K31/728 , A61K31/78 , A61K31/79 , A61K35/16 , A61K35/28 , A61K35/34 , A61K35/35 , A61K38/40 , A61K45/06 , A61K47/36 , A61L27/26 , A61L27/3804 , A61L27/3839 , A61L2430/20 , A61K2300/00 , C08L5/08
Abstract: Embodiments of single component bioscaffolding systems formed of a hydrogel such as hyaluronic acid or salt thereof are described. The hyaluronic acid or salt thereof may be dissolved in a buffer, plasma, or combination thereof to minimize adverse immunogenic responses when applied to a treatment site. Additionally, the hydrogel component includes stem cells to facilitate angiogenesis or facilitate tissue repair and/or regeneration of ischemic tissue, particularly in compromised cardiac tissue. The bioscaffolding may also be formed on a stent or a cardiac medical device.
Abstract translation: 描述了由诸如透明质酸或其盐的水凝胶形成的单组分生物支架系统的实施方案。 透明质酸或其盐可以溶解在缓冲液，血浆或其组合中，以在施用于治疗部位时使不利的免疫原性反应最小化。 此外，水凝胶组分包括促进血管发生的干细胞，或促进缺血组织的组织修复和/或再生，特别是在受损的心脏组织中。 生物支架也可以形成在支架或心脏医疗装置上。
-
3.发明申请Modified Two-Component Gelation Systems, Methods of Use and Methods of Manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US20100196313A1
公开(公告)日：2010-08-05
申请号：US12756092
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
公开(公告)号：US09533124B2
公开(公告)日：2017-01-03
申请号：US13086664
申请日：2011-04-14
Applicant: Matthew M. Mack , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
Inventor： Matthew M. Mack , Jeffrey Allen Spaeder , Kevin Joe Ehrenreich , John L. Toner , Paul Macke Consigny , Syed Faiyaz Ahmed Hossainy , Shubhayu Basu
CPC classification number: A61M25/1011 , A61F2/958 , A61M25/10182 , A61M25/10185 , A61M25/10188 , A61M25/104 , A61M2025/0004 , A61M2025/0006 , A61M2025/1013 , A61M2025/1015 , A61M2025/1052 , A61M2025/1079
Abstract: A catheter configured for performing reperfusion by alternatively occluding a vessel so as to prevent fluid flow and removing that occlusion to allow fluid flow is described. A first catheter includes an outer member and a retractable valve to allow and prevent fluid flow in the vessel. A second catheter includes a sheathed expansion member that can be deployed and recaptured to prevent and allow, respectively, fluid flow. A third catheter includes an angioplasty balloon to open a vessel occlusion, in which an occlusion balloon is used to allow and disallow fluid flow. A fourth catheter includes an expandable member for providing mechanical plunging action to urge thrombotic material to a more distal location. A fifth catheter includes an accessory catheter that can be used to perform reperfusion with another catheter. A sixth catheter includes an inner balloon within an outer balloon configured to perform reperfusion.
Abstract translation: 导管，被配置为通过交替地封闭容器进行再灌注，以便防止流体流动并且去除该阻塞以允许流体流动。 第一导管包括外部构件和可伸缩阀，以允许和防止流体在容器中流动。 第二导管包括可以展开和重新捕获以防止和允许流体流动的护套膨胀构件。 第三导管包括血管成形术球囊以打开血管闭塞，其中使用阻塞气囊来允许和禁止流体流动。 第四导管包括用于提供机械插入作用以将血栓形成材料推动到更远侧位置的可扩张构件。 第五导管包括可用于对另一个导管进行再灌注的辅助导管。 第六导管包括构造成执行再灌注的外气囊内的内气球。
-
5.发明授权Modified two-component gelation systems, methods of use and methods of manufacture 有权改进的双组分凝胶化系统，使用方法和制造方法公开(公告)号：US08486387B2
公开(公告)日：2013-07-16
申请号：US12756119
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
Abstract translation: 本文公开了组合物，制造方法和心肌梗死后治疗方法。 在一些实施方案中，组合物包含至少两种组分。 在一个实施方案中，第一组分可以包括第一官能化聚合物和具有至少一个细胞粘附位点的物质，其在约6.5的pH下在第一缓冲液中合并。 第二组分可以包括pH在约7.5和9.0之间的第二缓冲液。 第二官能化聚合物可以包括在第一或第二组分中。 在一些实施方案中，组合物可以包括至少一种细胞类型和/或至少一种生长因子。 在一些实施方案中，本发明的组合物可以通过双孔注射装置递送至治疗区域，例如心肌梗死后区域。
-
Patent Agency Ranking
公开(公告)号：US08486386B2
公开(公告)日：2013-07-16
申请号：US12756092
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
公开(公告)号：US20120252089A1
公开(公告)日：2012-10-04
申请号：US13525165
申请日：2012-06-15
Applicant: Shubhayu Basu , Gene Michal , Florian Ludwig , Jingping Wan , John Stankus
Inventor： Shubhayu Basu , Gene Michal , Florian Ludwig , Jingping Wan , John Stankus
IPC: C12N11/04
CPC classification number: A61L27/52 , A61L27/20 , A61L27/3604 , A61L27/3641 , A61L27/365 , A61L27/3804 , A61L27/3839 , C08L5/04
Abstract: The present invention relates to a method of making cytocompatible alginate gels and their use in the treatment of cardiomyopathy.
-
公开(公告)号：US20120237477A1
公开(公告)日：2012-09-20
申请号：US13481627
申请日：2012-05-25
Applicant: Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
Inventor： Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
CPC classification number: A61K9/0024 , A61K31/4439 , A61K31/557 , A61K31/56 , A61K38/195 , A61K38/27 , A61K38/30 , A61K47/36 , A61L27/26 , A61L27/52 , C08L5/08 , C08L89/06
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
公开(公告)号：US08187621B2
公开(公告)日：2012-05-29
申请号：US11447340
申请日：2006-06-05
Applicant: Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
Inventor： Eugene Michal , Shubhayu Basu , Hai-Chien Kuo
CPC classification number: A61K9/0024 , A61K31/4439 , A61K31/557 , A61K31/56 , A61K38/195 , A61K38/27 , A61K38/30 , A61K47/36 , A61L27/26 , A61L27/52 , C08L5/08 , C08L89/06
Abstract: Methods and compositions for treating post-myocardial infarction damage are herein disclosed. In some embodiments, a carrier with a treatment agent may be fabricated. The carrier can be formulated from a bioerodable, sustained-release substance. The resultant loaded carrier may then be suspended in at least one component of a two-component matrix system for simultaneous delivery to a post-myocardial infarction treatment area.
Abstract translation: 本文公开了治疗心肌梗死后损伤的方法和组合物。 在一些实施方案中，可以制造具有处理剂的载体。 载体可以由生物可蚀塑的缓释物质配制。 然后将所得负载载体悬浮在双组分基质系统的至少一个组分中，用于同时递送至心肌梗死后治疗区域。
-
公开(公告)号：US20100196314A1
公开(公告)日：2010-08-05
申请号：US12756119
申请日：2010-04-07
Applicant: Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
Inventor： Eugene Michal , Olof Mikael Trollsas , Shubhayu Basu
CPC classification number: A61K47/34 , A61K9/0024 , A61K9/06 , A61K35/12 , A61K38/00 , A61L27/26 , A61L27/38 , A61L27/50 , A61K2300/00
Abstract: Compositions, methods of manufacture and methods of treatment for post-myocardial infarction are herein disclosed. In some embodiments, the composition includes at least two components. In one embodiment, a first component can include a first functionalized polymer and a substance having at least one cell adhesion site combined in a first buffer at a pH of approximately 6.5. A second component can include a second buffer in a pH of between about 7.5 and 9.0. A second functionalized polymer can be included in the first or second component. In some embodiments, the composition can include at least one cell type and/or at least one growth factor. In some embodiments, the composition(s) of the present invention can be delivered by a dual bore injection device to a treatment area, such as a post-myocardial infarct region.
-
-
-
-
-
-
-
-
-
Search Results
40
records
(took 0.019 seconds)
